Abstract Background Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However. their improvement on progression-free survival (PFS) remains modest. potentially explained by tumor molecular heterogeneity. https://fitnessgravesyardes.shop/product-category/dc-wire-harness/